SCHEMBL14946362

SCHEMBL14946362

CNc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(Cl)Cl)[C@H](O)C1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 5/20 0.66
ADORA1 P30542 4/20 0.66
DNPH1 O43598 3/20 0.64
TAS1R3 Q7RTX0 2/20 0.64
TAS1R1 Q7RTX1 2/20 0.64
ADORA3 P0DMS8 2/20 0.62
P2RY2 P41231 3/20 0.62
SRC P12931 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
PRKAB2 O43741 1/20 0.62
TRPM2 O94759 1/20 0.62
LDHA P00338 1/20 0.62
ADRB2 P07550 1/20 0.62
FBP1 P09467 1/20 0.62
PRKAG1 P54619 1/20 0.62
PRKAA2 P54646 1/20 0.62
PDE4D Q08499 1/20 0.62
KCNH2 Q12809 1/20 0.62
PRKAA1 Q13131 1/20 0.62
PDE3A Q14432 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18574268 1.00 P2RY1 (0.66) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL14929511 1.00 P2RY1 (0.66) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL30584160 0.92 ADORA1 (0.77) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL26067680 0.92 DNPH1 (0.75) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL30004415 0.92 DNPH1 (0.75) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL14358316 0.92 ADORA1 (0.77) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL20266278 0.92 ADORA1 (0.77) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL4307198 0.92 DNPH1 (0.75) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL14358309 0.91 DNPH1 (0.74) P2RY1ADORA1DNPH1TAS1R3TAS1R1
SCHEMBL26067558 0.91 DNPH1 (0.66) P2RY1ADORA1DNPH1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 P2RY1 386/4885ADORA1 161/4885DNPH1 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.